Hemab Therapeutics Holdings, Inc. current report, 24 September 2026

Filing Overview

Hemab Therapeutics Holdings, Inc. filed a Form 8-K dated September 24, 2026, under Item 5.02 regarding the appointment of a new director and related compensation arrangements. The company is incorporated in Delaware, trades under the symbol COAG on Nasdaq Global Select Market, and identifies as an emerging growth company.

Board Appointment and Compensation

  • Keli Walbert was elected to the Board effective September 24, 2026, as a Class I director. Her term expires at the 2027 annual meeting of stockholders, subject to earlier termination or successor appointment.
  • Ms. Walbert was appointed to the Audit Committee.
  • She will receive an option to purchase 36,000 common shares, with an exercise price equal to the September 24, 2026 closing stock price. The option vests in equal monthly installments through the third anniversary of the grant date, subject to continued service.
  • All option vesting accelerates upon a change in control of the company.
  • Annual cash compensation includes $40,000 for Board service and an additional $10,000 for Audit Committee service. She is also eligible for annual equity grants and reimbursement of reasonable Board-related travel and out-of-pocket expenses.
  • Ms. Walbert will enter into the company’s standard indemnification agreement, which may require indemnification for certain expenses, judgments, fines, and settlements arising from her service as a director.

Financial Metrics and Liquidity

The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other operating and financial metrics. It is not a financial results filing.

Material Changes, Outlook, and Risks

  • The material change disclosed is the addition of Ms. Walbert to the Board and Audit Committee.
  • The filing states that there are no arrangements or understandings related to her election, no family relationships with the company’s directors or executive officers, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
  • The option’s change-in-control acceleration and the indemnification obligations represent potential future corporate obligations, but the filing does not quantify their value or potential exposure.
  • No guidance, business outlook, contingencies, or unusual operating items are disclosed.

Investor Verification Points

  • Confirm the September 24, 2026 closing price used as the option exercise price.
  • Review the company’s non-employee director compensation policy and the final option agreement.
  • Assess the effect of the 36,000-share option and future annual equity grants on potential dilution.
  • Review the referenced indemnification agreement filed as Exhibit 10.9 to Amendment No. 1 to the company’s Form S-1.
  • Monitor future filings for changes to Board committee composition, director compensation, or change-in-control provisions.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.